Why FibroBiologics, Inc.’s (FBLG) Stock Is Down 5.07%
As of Tuesday, April 22, FibroBiologics, Inc.’s FBLG share price has dipped by 5.07%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Commentary & Analysis
Why FibroBiologics, Inc.’s (FBLG) Stock Is Down 25.43%
As of Thursday, February 13, FibroBiologics, Inc.’s FBLG share price has dipped by 25.43%, which has investors questioning if this is right time to buy.Tudor Pop
Why FibroBiologics, Inc.’s (FBLG) Stock Is Up 16.25%
As of Friday, February 07, FibroBiologics, Inc.’s FBLG share price has surged by 16.25%, which has investors questioning if this is right time to sell.Tudor Pop
Financial Summary
| Share Statistics | FBLG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $8.4 | $250.6 | 6% |
|
| Shares Out (Mil) | 6.3 | 54.0 | 16% |
|
| Institutional Ownership | 42.5% | 93.1% | 18% |
|
| Float (Mil) | 6.0 | 41.4 | 14% |
|
| Beta | 1.17 | 0.95 | 69% |
|
| Avg Daily Volume (000s) | 143 | 720 | 38% |
|
| Price Change (52-week) |
(89.0%) | 49.4% | 5% |
|
| Growth | FBLG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (73.0%) | (10.2%) | 4% |
|
| EPS (5yr) | (25.6%) | 15.7% | 10 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.630) | ($3.000) | ($3.250) | |
| Month Ago EPS | ($0.630) | ($3.000) | ($3.250) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.940) | ($4.010) | ($4.490) | |
| Year/Year Chg | (4.0%) | (64.1%) | (52.1%) | |
| Financials | FBLG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $36 | na |
|
| Net Income (TTM) (Mil) | ($18) | ($44) | 25% |
|
| EPS (TTM) | ($4.766) | ($1.600) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($33) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 17% |
|
| Enterprise Value (Q1) (Mil) | $3 | $174 | 4% |
|
| Valuation | FBLG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.59 | 2.41 | 44% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | FBLG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (166.1%) | (47.7%) | 3% |
|
| ROE | (660.1%) | (55.0%) | 1% |
|
| Liabilities to Assets | 41.5% | 29.3% | 32% |
|
| F-Score | 3 | 3 | 18% |
|
FibroBiologics, Inc. did not pass any screens on 10/1/2026.
